Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer (Q38577715)

4 September 2017

title

Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer (English)

1 reference

4 September 2017

Neha S Mangini

1

1 reference

4 September 2017

Robert Wesolowski

2

1 reference

4 September 2017

Bhuvaneswari Ramaswamy

3

1 reference

4 September 2017

Maryam B Lustberg

4

1 reference

4 September 2017

Michael J Berger

5

1 reference

4 September 2017

language of work or name

English

0 references

publication date

31 August 2015

1 reference

Annals of Pharmacotherapy

4 September 2017

published in

1 reference

4 September 2017

volume

49

1 reference

4 September 2017

issue

11

1 reference

4 September 2017

page(s)

1252-1260

1 reference

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

Endocrine therapy in the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficac

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

Combination anastrozole and fulvestrant in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

Cyclin-dependent kinase pathways as targets for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

Cyclin D as a therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

Molecular pathways: CDK4 inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

PD0332991 (palbociclib) for treatment of pediatric intracranial growing teratoma syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

CDK 4/6 inhibitor palbociclib (PD0332991) in Rb advanced breast cancer: phase II activity, safety, and predictive biomarker assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1060028015602273

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26324355

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26324355

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1177/1060028015602273

1 reference

4 September 2017

0 references

1 reference